High throughput screening techniques to inform on compound liability and solubility to advance the PROTAC® platform Read More »
A phase 2 expansion study of ARV-766, a PROTAC® androgen receptor degrader, in metastatic castration-resistant prostate cancer – Poster Presentation Read More »
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer – PLS Read More »
The Arvinas PROTAC® Discovery Engine: Insights from Discovering & Developing Molecules That Induce Targeted Protein Degradation Read More »
ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study Read More »
Orally Administered PROTAC® Molecules Selectively Clear Pathologic Proteins in CNS & Muscle Read More »
In Vitro Evaluation Of PROTAC® Degrader ARV-110 (Bavdegalutamide) For Cytochrome P450- And Transporter-Mediated Drug-Drug Interaction Read More »
Phase 1b study of Bavdegalutamide, an androgen receptor PROTAC® degrader, combined with abiraterone in patients with metastatic prostate cancer Read More »
